Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2-positive Breast Cancer × trastuzumab deruxtecan × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Neoplasm Metastasis 8 Brain Neoplasms 6 Stomach Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasms 2 Neoplasm, Residual 2 Meningeal Carcinomatosis 2 Carcinoma, Non-Small-Cell Lung 2 Breast Cancer With Brain Metastasis 2 Advanced Breast Cancer 2 Salivary Gland Neoplasms 1 Ovarian Neoplasms 1 HER2-positive Breast Cancer 1 HER2-negative Breast Cancer 1 HER2 Overexpression 1 Glioblastoma 1 Gastric Adenocarcinoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1

Interventions

Trastuzumab 19 pyrotinib 14 pertuzumab 8 Docetaxel 7 Paclitaxel 6 Capecitabine 4 Carboplatin 3 neratinib 2 Protons 2 Fulvestrant 2 Ado-Trastuzumab Emtansine 2 tucatinib 1 trastuzumab deruxtecan 1 pegfilgrastim 1 palbociclib 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 atezolizumab 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Goserelin 1 Genetic Testing 1 Fluorodeoxyglucose F18 1 Enfuvirtide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05982678 2025-11-26

ANISE

The Netherlands Cancer Institute

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡